Stockscreener 앱 받기
2.66
1.12%
-0.03
시장 영업 전:
2.93
0.27
+10.15%
Nrx Pharmaceuticals Inc 주식(NRXP)의 최신 뉴스
Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) Q2 Earnings Lag Estimates - Zacks Investment Research
NRx Pharmaceuticals (NasdaqCM:NRXP) Stock Forecast & Analyst Predictions - Simply Wall Street
Total common shares outstanding of NRX Pharmaceuticals, Inc. – HAN:B1Q - TradingView
ADARx Pharmaceuticals Announces Pricing of Upsized $446.3 Million Initial Public Offering - Yahoo Finance
FDA-Cleared Zeta TMS Robotic System Moves Toward Deployment as FDA, DARPA and Commercial Catalysts Converge: NRx Pharmaceuticals (N A S D A Q: NRXP) - FinancialContent
NRXP: Preservative-free ketamine and robotic TMS drive innovation, with FDA decision expected soon - TradingView
NRx Pharmaceuticals at Cantor conference: ketamine push gains momentum By Investing.com - Investing.com Canada
NRx Pharmaceuticals Subsidiary HOPE Therapeutics Begins Training and Deployment of Zeta Surgical's FDA-Cleared Robotic TMS System - Investing News Network
NRx deploys FDA-cleared robotic TMS system in Florida - grafa.com
NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Begins Training and Deployment of Zeta Surgical's FDA-Cleared Robotic TMS System - Yahoo Finance
NRx Pharmaceuticals to Present at Three September Investor Conferences - citybiz
NRx Pharmaceuticals to Participate in Upcoming Investor Conferences - Yahoo Finance
Nasus Pharma Files $50 Million Shelf Registration - Yahoo Finance
New to The Street's Prestigious Client NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Notification of US Food and Drug Administration Approval of Suitability Petition for NRx's Proposed Strength of Preservative-Free Ketamine - The Ithaca Journal
NRx Pharmaceuticals (NASDAQ:NRXP) Downgraded by Zacks Research to Strong Sell - MarketBeat
VolitionRx Files for Secondary Offering of Common Shares - Yahoo Finance
H.C. Wainwright reiterates Buy on NRx Pharmaceuticals stock at $45 - Investing.com
H.C. Wainwright reiterates Buy on NRx Pharmaceuticals stock at $45 By Investing.com - Investing.com India
H.C. Wainwright reiterates Buy on NRx Pharmaceuticals stock at $45 By Investing.com - Investing.com UK
NRx Advances Ketamine Bid After FDA Review Clears Drug - MyChesCo
FDA First Cycle Review of Preservative-Free Ketamine ANDA with No Drug Related Major Deficiencies Noted for Suicidal Bipolar Depression Treatment from NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) - barchart.com
NRX (NRXP) Momentum: Ends Higher by 5.41% at $3.51 for the Current Session; the Current Price Sits Inside the Supplied Technical RangeIV Contraction - Vinanet
NRx cites arbitration in Kadima acquisition dispute - scanx.trade
FDA First Cycle Review of Preservative-Free Ketamine ANDA with No Drug Related Major Deficiencies Noted for Suicidal Bipolar Depression Treatment from NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) - FinancialContent
Nrx Pharmaceuticals Earnings Call Signals Cautious Momentum - TipRanks
NRx Pharmaceuticals, Inc. (NRXP) Stock Price, News, Quote & History - Yahoo Finance
NRx Pharmaceuticals Targets 2026 KETAFREE Approval, Advances DARPA-Backed Depression Trial - citybiz
NRx Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
BTIG Maintains NRX Pharmaceuticals(NRXP.US) With Buy Rating, Cuts Target Price to $10 - moomoo.com
BTIG Research Reaffirms "Buy" Rating for NRx Pharmaceuticals (NASDAQ:NRXP) - MarketBeat
NRx Pharmaceuticals (Nasdaq:NRXP) Reports Second Quarter 2026 Financial Results and Provides Corporate Update - marketscreener.com
NRX Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcript - Benzinga
NRX Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
NRx Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update; Conference Call to be Held on Monday, August 17th at 4:30pm ET - Investing News Network
NRX Pharmaceuticals Q2 Results: EPS Misses Estimate, Sales Fall 94% - scanx.trade
NRX Pharmaceuticals reports $18.0M net loss for first half 2026, $26.7M cash on hand - TradingView
Five million ketamine doses are in production—but when can sales start? - Stock Titan
Press Release: NRx Pharmaceuticals (Nasdaq:NRXP) Reports Second Quarter 2026 Financial Results and Provides Corporate Update; Conference Call to Be Held on Monday, August 17th at 4:30pm ET - Moomoo
NRx Pharmaceuticals (Nasdaq:NRXP) Reports Second Quarter 2026 Financial Results and Provides Corporate Update; Conference Call to be Held on Monday, August 17th at 4:30pm ET - GlobeNewswire
NRx Pharmaceuticals (Nasdaq:NRXP) Reports Second Quarter 2026 Financial Results and Provides Corporate Update; Conference Call to be Held on Monday, August 17th at 4:30pm ET - Yahoo Finance
NRX Pharmaceuticals Inc (NRXP) (Q2 2026) Earnings Call Highlights: Advancing Ketamine Pipeline ... - Yahoo Finance
NRx Pharmaceuticals, Inc. (NRXP) reports Q2 loss, misses revenue estimates - FXStreet
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
NRx Pharmaceuticals (NASDAQ:NRXP) Downgraded to "Sell" Rating by Wall Street Zen - MarketBeat
NRx Pharmaceuticals (NASDAQ:NRXP) Issues Earnings Results, Misses Estimates By $0.35 EPS - MarketBeat
NRx Pharmaceuticals, Inc. (NRXP) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
NRX Pharmaceuticals | 10-Q: Q2 2026 Earnings Report - Moomoo
NRx Pharmaceuticals (NRXP) grows clinic revenue, flags going concern risk - Stock Titan
NRX Pharmaceuticals Inc expected to post earnings of 6 cents a shareEarnings Preview - TradingView
NRXP Q2'26 Earnings: EPS estimate is (0.11) USD - TradingView
2.14%
자본화:
|
볼륨(24시간):